Daniel S. Chen
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers 31
- CAR-T cell therapy research 14
- Immunology top 0.1%
- Immunotherapy and Immune Responses 18
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 5
- Pulmonary and Respiratory Medicine top 0.2%
- Ferroptosis and cancer prognosis 4
- Molecular Biology top 1%
-
- Bladder and Urothelial Cancer Treatments 6
-
- Monoclonal and Polyclonal Antibodies Research 6
-
- Cancer Research and Treatments 4
- Co-authors
- Ira MellmanPriti S. HegdeNapoleone FerraraRajendra S. ApteThomas PowlesF. Stephen HodiGregg FineBryan Irving
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Journal of Clinical Oncology (12 papers)Cancer Research (6 papers)Clinical Cancer Research (4 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Daniel S. Chen
49 papers receiving 19.7k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Oncology 13.3k
- Immunology 8.5k
- Cancer Research 2.6k
- Pulmonary and Respiratory Medicine 4.6k
- Molecular Biology 5.1k
Countries citing papers authored by Daniel S. Chen
This map shows the geographic impact of Daniel S. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Chen more than expected).
Fields of papers citing papers by Daniel S. Chen
This network shows the impact of papers produced by Daniel S. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Chen. The network helps show where Daniel S. Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Daniel S. Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The cancer-immunity cycle: Indication, genotype, and immunotypebreakdown → | 2023 | 444 |
| 2 | 2022 | 7 | |
| 3 | Top 10 Challenges in Cancer Immunotherapybreakdown → | 2020 | 1442 |
| 4 | 2019 | 58 | |
| 5 | 2018 | 152 | |
| 6 | 2018 | 242 | |
| 7 | Elements of cancer immunity and the cancer–immune set pointbreakdown → | 2017 | 3575 |
| 8 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialbreakdown → | 2016 | 2112 |
| 9 | 2016 | 22 | |
| 10 | 2014 | 21 | |
| 11 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerbreakdown → | 2014 | 1850 |
| 12 | Oncology Meets Immunology: The Cancer-Immunity Cyclebreakdown → | 2013 | 4864 |
| 13 | 2012 | 152 | |
| 14 | 2012 | 18 | |
| 15 | 2011 | 79 | |
| 16 | 2011 | 148 | |
| 17 | 2007 | 25 | |
| 18 | 2005 | 10 | |
| 19 | 2005 | 76 | |
| 20 | 1997 | 39 |
About Daniel S. Chen
Daniel S. Chen is a scholar working on Oncology, Immunology and Biotechnology, having authored 50 papers that have together received 20.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (31 papers), Immunotherapy and Immune Responses (18 papers), CAR-T cell therapy research (14 papers), Bladder and Urothelial Cancer Treatments (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Cancer Genomics and Diagnostics (5 papers), Cancer Research and Treatments (4 papers) and Ferroptosis and cancer prognosis (4 papers). The work is most often cited by research in Oncology (13.3k citations), Immunology (8.5k citations) and Cancer Research (2.6k citations). Daniel S. Chen has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Ira Mellman, Priti S. Hegde, Napoleone Ferrara, Rajendra S. Apte, Thomas Powles, F. Stephen Hodi, Gregg Fine, Bryan Irving, Marcin Kowanetz and Marcus Ballinger. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Immunity and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.